SOLIGENIX, INC. (ticker: SNGX) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of SNGX's SEC filings surfaces 4 active risk signals, including 2 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. SNGX reported $119K in revenue and -$2.82M for the period ending 2024-12-31, with operating cash flow of -$2.36M. Cash and equivalents stood at $6.03M (down 17.4% year-over-year). Total assets of $6.92M exceed total liabilities of $3.83M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
SNGX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for SOLIGENIX, INC. (SNGX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.